MedPath

Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Registration Number
NCT00311610
Lead Sponsor
Alliance for Clinical Trials in Oncology
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as liposomal SN-38, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well liposomal SN-38 works in treating patients with metastatic colorectal cancer.

Detailed Description

OBJECTIVES:

Primary

* Determine the objective response rate following treatment with SN-38 liposome as a second-line treatment in patients with metastatic colorectal cancer.

Secondary

* Determine the toxicity profile of this drug in these patients.

* Determine the proportion of patients treated with this drug who experience any grade 3 or greater toxicity.

* Determine progression-free survival and overall survival for patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for up to 3 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SN-38 liposomeSN-38 liposomePatients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for up to 3 years.
Primary Outcome Measures
NameTimeMethod
Objective response rateq 2 cycles during tx
Secondary Outcome Measures
NameTimeMethod
Toxicityq cycle during tx
Progression-free survival3 years
Overall survival3 years

Trial Locations

Locations (10)

Tunnell Cancer Center at Beebe Medical Center

🇺🇸

Lewes, Delaware, United States

Kaiser Permanente Medical Office -Vandever Medical Office

🇺🇸

San Diego, California, United States

Union Hospital Cancer Program at Union Hospital

🇺🇸

Elkton MD, Maryland, United States

CCOP - Christiana Care Health Services

🇺🇸

Newark, Delaware, United States

University Medical Center of Southern Nevada

🇺🇸

Las Vegas, Nevada, United States

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

CCOP - Nevada Cancer Research Foundation

🇺🇸

Las Vegas, Nevada, United States

Kinston Medical Specialists

🇺🇸

Kinston, North Carolina, United States

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

🇺🇸

Columbus, Ohio, United States

Cancer Institute of New Jersey at Cooper - Voorhees

🇺🇸

Voorhees, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath